Vitruvian Networks, will serve as a network orchestrator for therapeutic companies with powerful business intelligence and data analytics capabilities.
Called GADGET-PD, the trial will use wireless sensors and genetic sequencing to determine if a patient has essential tremor (ET) from Parkinson's disease (PD).
Researchers are now able to design targeted studies for diseases and conditions, and to gather more specific types of data from participants.
Knome's knoSYS tech brings maximum value to the already robust genome informatics offerings at Tute, used by many of the top institutions across the world.
Called Personal Genome Service, it is touted as an entirely new experience that includes carrier status, wellness, trait and ancestry reports.
The new funds will help the personal genetics company launch new global user experience, grow its sales efforts and therapeutics discovery group efforts.
The Pathway Fit genetic test analyzes over 75 genetic markers known to impact metabolism, exercise, and energy consumption use within the human body.
The platform will enable next generation sequencing (NGS) researchers to share and cross-validate their tests/results against crowd-sourced reference material.
The company will use the funds to build its bioinformatics infrastructure, enhance sequencing facilities, and expand its research and scientific teams.
The two parties will explore the role of genetics and its influences in families experiencing unusual longevity using Ancestry's databases, tools and algorithms.